Neel Desai, MD
Ophthalmology · Largo, FLNPI 1609957786
Payments from drug & device makers
Across 835 payments — averaging $1255.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$399K
- Alcon$205K
- Sight Sciences, Inc.$89K
- Bausch & Lomb Americas Inc.$54K
- Alcon Research LLC$54K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$50K
- plus $199K from 27 others
Across 2 payments — averaging $6300.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biotissue Holdings Inc.$13K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 160 | $398,744 |
| Alcon | 181 | $204,590 |
| Sight Sciences, Inc. | 74 | $89,106 |
| Bausch & Lomb Americas Inc. | 53 | $53,672 |
| Alcon Research LLC | 14 | $53,569 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 57 | $49,608 |
| Sun Pharmaceutical Industries Inc. | 50 | $36,316 |
| Kala Pharmaceuticals, Inc. | 44 | $27,577 |
| Dompe US, Inc. | 26 | $26,574 |
| Glaukos Corporation | 47 | $23,524 |
| Nordic Pharma, Inc. | 2 | $20,236 |
| Johnson & Johnson Surgical Vision, Inc. | 32 | $13,700 |
| Eyevance Pharmaceuticals LLC | 15 | $10,580 |
| Novartis | 14 | $9,598 |
| Shire North American Group Inc | 12 | $9,152 |
| Lumenis, Inc | 1 | $8,411 |
| AbbVie(2 entities) | 9 | $5,357 |
| Carl Zeiss Meditec, Inc. | 2 | $4,400 |
| Eyepoint US, Inc. | 3 | $1,356 |
| Omeros Corporation | 2 | $559 |
| Carl Zeiss Meditec USA, Inc. | 5 | $369 |
| Topcon Healthcare, Inc. | 4 | $290 |
| Amgen(2 entities) | 7 | $235 |
| Harrow Eye, LLC | 5 | $144 |
| NEW World Medical,inc. | 2 | $130 |
| Carl Zeiss Meditec Cataract Technology Inc. | 4 | $91 |
| Rxsight Inc | 2 | $89 |
| Lensar, Inc. | 1 | $64 |
| ANI Pharmaceuticals, Inc. | 2 | $59 |
| Coopervision Inc. | 1 | $54 |
| Oyster Point Pharma, Inc. | 2 | $41 |
| Tarsus Pharmaceuticals, Inc. | 1 | $32 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
How this compares
$1,048,247 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Largo
- Philip ShettleLargo$1.6M
- Robert WeinstockLargo$855K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.